SG10202010355PA - Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof - Google Patents

Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof

Info

Publication number
SG10202010355PA
SG10202010355PA SG10202010355PA SG10202010355PA SG10202010355PA SG 10202010355P A SG10202010355P A SG 10202010355PA SG 10202010355P A SG10202010355P A SG 10202010355PA SG 10202010355P A SG10202010355P A SG 10202010355PA SG 10202010355P A SG10202010355P A SG 10202010355PA
Authority
SG
Singapore
Prior art keywords
coq10
coenzyme
methods
intravenous formulations
intravenous
Prior art date
Application number
SG10202010355PA
Other languages
English (en)
Inventor
Niven Narain
John Mccook
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44564137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202010355P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG10202010355PA publication Critical patent/SG10202010355PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10202010355PA 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof SG10202010355PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31363210P 2010-03-12 2010-03-12
US38510710P 2010-09-21 2010-09-21

Publications (1)

Publication Number Publication Date
SG10202010355PA true SG10202010355PA (en) 2020-11-27

Family

ID=44564137

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2012063418A SG183508A1 (en) 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
SG10201501872XA SG10201501872XA (en) 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
SG10202010355PA SG10202010355PA (en) 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2012063418A SG183508A1 (en) 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
SG10201501872XA SG10201501872XA (en) 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof

Country Status (26)

Country Link
US (2) US11400058B2 (es)
EP (2) EP2544663B1 (es)
JP (4) JP5968231B2 (es)
KR (2) KR102008658B1 (es)
CN (2) CN105168135A (es)
AU (4) AU2011224207B2 (es)
BR (1) BR112012022916B1 (es)
CA (2) CA2791693C (es)
CL (1) CL2012002507A1 (es)
CO (1) CO6620033A2 (es)
CR (1) CR20120507A (es)
CY (1) CY1120290T1 (es)
DK (1) DK2544663T3 (es)
EA (1) EA032941B1 (es)
ES (1) ES2664793T3 (es)
HK (1) HK1219055A1 (es)
IL (1) IL221675B (es)
MX (1) MX344078B (es)
MY (1) MY163995A (es)
NZ (3) NZ720022A (es)
PE (1) PE20130045A1 (es)
PL (1) PL2544663T3 (es)
PT (1) PT2544663T (es)
SG (3) SG183508A1 (es)
TW (2) TWI610671B (es)
WO (1) WO2011112900A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120060945A (ko) 2009-05-11 2012-06-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자, 다차원 세포내 분자 또는 환경적 영향인자를 사용한 대사적 장애의 치료 방법
MY163995A (en) 2010-03-12 2017-11-15 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
JP6092844B2 (ja) * 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
MX369543B (es) 2011-06-17 2019-11-12 Berg Llc Composiciones farmaceuticas inhalables.
CA2875150C (en) * 2012-06-01 2020-10-27 Berg Llc Treatment of solid tumors using coenzyme q10
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
EP3730131A1 (en) * 2013-09-04 2020-10-28 Berg LLC Methods of treatment of cancer by continuous infusion of coenzyme q10
IN2014CH01872A (es) * 2014-04-09 2015-05-08 Nanoceutica Lab Pvt Ltd
CA2936070C (en) * 2015-07-14 2023-07-04 Professional Compounding Centers Of America (Pcca) Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents
US20170189350A1 (en) * 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3634391A4 (en) 2017-05-17 2021-02-24 Berg LLC USE OF COENZYME Q10 FORMULATIONS IN THE TREATMENT AND PREVENTION OF BUBBLE EPIDERMOLYSIS
EP3768829A4 (en) 2018-02-01 2022-02-09 The Royal Institution for the Advancement of Learning / McGill University FORMULATIONS TO ENHANCE DELIVERY OF HYDROPHOBIC AGENTS
SG11202009788TA (en) * 2018-04-09 2020-10-29 Orgenesis Inc Bioxomes particles, redoxomes, method and composition
US20200138744A1 (en) * 2018-10-15 2020-05-07 Berg Llc Methods of treating pancreatic cancer using coenzyme q10
IL268457B (en) 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil suspension of edible solids and methods of preparation
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma
WO2023120553A1 (ja) * 2021-12-24 2023-06-29 株式会社カネカ 還元型補酵素ｑ１０の保存方法

Family Cites Families (349)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
JPS5612309A (en) 1979-07-11 1981-02-06 Kyowa Hakko Kogyo Co Ltd Oral drug containing ubidecarenone
JPS5618914A (en) 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
JPS56109590A (en) 1980-02-05 1981-08-31 Zeria Shinyaku Kogyo Kk Production of clathrate compound of coenzyme q10
JPS588010A (ja) 1981-07-08 1983-01-18 Eisai Co Ltd ユビデカレノン含有リポソ−ム
IT1157269B (it) 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
JPS59148718A (ja) 1983-02-10 1984-08-25 Fujisawa Pharmaceut Co Ltd ユビデカレノン組成物
JPS59148735A (ja) 1983-02-14 1984-08-25 Fujisawa Pharmaceut Co Ltd ユビデカレノン組成物
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
JPS601124A (ja) 1983-06-16 1985-01-07 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US5220042A (en) 1984-01-26 1993-06-15 Otsuka Pharmaceutical Co., Ltd. 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same
JPS60199814A (ja) 1984-03-24 1985-10-09 Taisho Pharmaceut Co Ltd ユビデカレノン脂肪乳剤
GB8423436D0 (en) 1984-09-17 1984-10-24 Riker Laboratories Inc Preparation of liposomes
IT1191608B (it) 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
US4824669A (en) 1985-04-11 1989-04-25 Board Of Regents, The University Of Texas System Formulations of coenzyme Q10 for intravenous use
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
DE3524788A1 (de) 1985-07-11 1987-01-22 Lentia Gmbh Stabile, intravenoes applizierbare, waessrige fettemulsion und ein verfahren zu deren herstellung
JPH0665645B2 (ja) 1985-09-18 1994-08-24 日清製粉株式会社 自己乳化型軟カプセル薬液
JPS62123113A (ja) 1985-11-22 1987-06-04 Green Cross Corp:The ユビデカレノン含有脂肪乳剤
SE8603812D0 (sv) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
IT1214540B (it) 1986-10-23 1990-01-18 Vincenzo Zappia Mario De Rosa Formulazioni idrosolubili di ubidecarenoni, procedimento per laloro preparazione e composizioni farmaceutiche che li compongono.
JPS63188623A (ja) 1987-01-31 1988-08-04 Taisho Pharmaceut Co Ltd 吸収改善ユビデカレノン製剤
JPS63313727A (ja) 1987-06-17 1988-12-21 Noriyoshi Saeki 外用治療剤
JP2512310B2 (ja) 1987-06-24 1996-07-03 エーザイ株式会社 被覆脂肪乳剤
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
GB8811410D0 (en) 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5962243A (en) 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
JP3008131B2 (ja) 1990-11-14 2000-02-14 ロレアル グリセリンから誘導される非イオン両親媒性化合物、その調製方法、相応する中間体化合物及び前記化合物を含有する組成物
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
SE502569C2 (sv) 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
IT1250672B (it) 1991-07-11 1995-04-21 Idb Holding Spa Formulazioni orali di ubidecarenone in soluzione acquosa
US5378461A (en) 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US6461593B1 (en) 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
AU676470B2 (en) 1992-02-24 1997-03-13 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
IT1256386B (it) 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
EP0616801B1 (de) 1993-03-24 1998-05-27 Novartis AG Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (de) 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
US20020049422A1 (en) 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
ATE221919T1 (de) 1994-05-06 2002-08-15 Beckman Coulter Inc In flüssiger form stabiler thiolaktivator
JPH10509732A (ja) 1994-12-06 1998-09-22 ライアン・ファーマスーティカルス・インコーポレーテッド 水溶性ユビキノン組成物、プロドラッグおよびこれに関連した方法
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5539021A (en) 1995-06-05 1996-07-23 The Dow Chemical Company Process for preparing high internal phase ratio emulsions and latexes derived thereof
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
DE19537027A1 (de) 1995-10-05 1997-04-10 Beiersdorf Ag Hautpflegemittel für alte Haut
JP2000502087A (ja) 1995-12-15 2000-02-22 ナショナル リサーチ カウンシル オブ カナダ アジュバンドおよび送達賦形剤としての、アーケオソーム類、補酵素ｑ▲下１０▼を含有するアーケオソーム類、および補酵素ｑ▲下１０▼を含有する他の種類のリポソーム類
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (de) 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
DE19647352C2 (de) 1996-11-15 2000-06-29 Aqua Nova Getraenketechnologie Nicht alkoholisches Getränk mit einem Gehalt an Q 10
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
EP1007021B1 (de) 1997-02-11 2001-06-13 MSE Pharmazeutika GmbH Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
WO1998035658A2 (de) 1997-02-12 1998-08-20 Mse Pharmazeutika Gmbh Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
CA2281684C (en) 1997-02-28 2006-08-29 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US5900230A (en) 1997-08-18 1999-05-04 Squigle, Inc. Dental products to treat and prevent periodontal disease
WO1999011242A1 (en) 1997-09-04 1999-03-11 Biozone Laboratories, Inc. Oral liposomal delivery system
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
AU1289899A (en) 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
CA2736981A1 (en) 1998-04-14 1999-10-21 Kyowa Hakko Bio Co., Ltd. Process for producing isoprenoid compounds by microorganisms
US6503523B2 (en) 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
ATE233549T1 (de) 1998-06-19 2003-03-15 Skyepharma Canada Inc Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm
DE19828081C2 (de) 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W/O-Emulsionsgrundlagen
AU4908699A (en) 1998-07-16 2000-02-07 Cognis Deutschland Gmbh Use of pit emulsions
US6048886A (en) 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6200550B1 (en) 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US20020048551A1 (en) 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
EP1064913B1 (de) 1999-07-02 2005-09-14 Cognis IP Management GmbH Mikrokapseln - III
US6334999B1 (en) 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6630160B1 (en) 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US20030104080A1 (en) 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
JP2003518033A (ja) 1999-12-20 2003-06-03 コグニス・フランス・ソシエテ・アノニム 化粧品製剤および／または医薬製剤
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
FR2804864B1 (fr) 2000-02-11 2003-04-04 Serobiologiques Lab Sa Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
DE10007322A1 (de) 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Perlglanzmittel
ATE479419T1 (de) 2000-02-17 2010-09-15 Basf Se Wässrige dispersion wasserunlöslicher organischer uv-filtersubstanzen
FR2805464B1 (fr) 2000-02-25 2003-02-14 Serobiologiques Lab Sa Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis
DE10009996B4 (de) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP1272144A4 (en) 2000-03-27 2006-04-26 Schott Ag NEW COSMETIC BODY CLEANING AGENT AND FOOD SUPPLEMENTS CONTAINING BIOACTIVE GLASS AND METHODS FOR THE PREPARATION AND USE THEREOF
US6447760B2 (en) 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
US6468552B1 (en) 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
DE10031703A1 (de) 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
EP1170015A1 (de) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Verwendung von Extrakten des Pilzes Grifola frondosa
DE10033022A1 (de) 2000-07-07 2002-01-17 Cognis Deutschland Gmbh Aerosole
DE10034619A1 (de) 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
DE10036655A1 (de) 2000-07-26 2002-02-07 Basf Ag Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10036799A1 (de) 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2813195B1 (fr) 2000-08-29 2003-04-04 Serobiologiques Lab Sa Utilisation d'extraits de la plante cassia alata dans des produits de soin
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10048260A1 (de) 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10053328A1 (de) 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20070003536A1 (en) 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
DE10064818A1 (de) 2000-12-22 2002-06-27 Basf Ag Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (fr) 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection
NL1017205C2 (nl) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinale en cosmetische toepassing van hop en co-enzym Q10.
AU2002243760A1 (en) 2001-01-30 2002-08-12 Board Of Regents University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
EP1475083B1 (de) 2001-02-11 2007-12-26 Aquanova AG Verfahren zur Herstellung eines Wirkstoffkonzentrats sowie Wirkstoffkonzentrat
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
DE10113046A1 (de) 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
DE10113050A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden
DE10113053A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden
ATE327006T1 (de) 2001-03-23 2006-06-15 Oreal Hautbehandlungsmittel enthaltend fasern und ubichinone
US20030031688A1 (en) 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
DE10118269A1 (de) 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6686485B2 (en) 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (ja) 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
DE10123771B4 (de) 2001-05-16 2019-01-10 Beiersdorf Ag Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
EP1260212A1 (de) 2001-05-21 2002-11-27 Cognis France S.A. Kosmetische Mittel
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
EP1262167A1 (de) 2001-06-01 2002-12-04 Cognis France S.A. Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen
US6506915B1 (en) 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (fr) 2001-06-15 2004-06-11 Cognis France Sa Melanges de tensioactifs
SE0102380D0 (sv) 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
DE10133198A1 (de) 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
JP2003020495A (ja) 2001-07-10 2003-01-24 Cognis Japan Ltd 油脂組成物
DE10133305B4 (de) 2001-07-12 2004-06-03 Aquanova German Solubilisate Technologies (Agt) Gmbh Ubichinon Konzentrat
CH695085A5 (de) 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
US7414720B2 (en) 2001-07-27 2008-08-19 Herbert Wachtel Measuring particle size distribution in pharmaceutical aerosols
US20050142665A1 (en) 2003-12-23 2005-06-30 Boehringer Ingelheim International Gmbh Laser diffraction method for particle size distribution measurements in pharmaceutical aerosols
CN1561218A (zh) 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
US6699464B1 (en) 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
EP1281392A1 (de) 2001-08-02 2003-02-05 Cognis France S.A. Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte
DE10139580A1 (de) 2001-08-10 2003-02-20 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren
EP1423096B1 (en) 2001-08-29 2006-08-16 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
DE10143962A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143964A1 (de) 2001-09-07 2003-03-27 Basf Ag Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon
DE10143963A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
AU2002339555B2 (en) 2001-09-18 2007-03-01 Ciba Specialty Chemicals Holding Inc. Use of guaiol for treating the skin
DE10150725A1 (de) 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
EP1438017B1 (de) 2001-10-26 2006-05-10 Cognis IP Management GmbH Imprägnierlösung für kosmetiktücher
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
DE10155769A1 (de) 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10160682A1 (de) 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Emollients und kosmetische Zusammensetzungen
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162026A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Perlglanzkonzentrate
DE10162351A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
US20030129253A1 (en) 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
US6696082B2 (en) 2002-01-08 2004-02-24 Mccully Kilmer S. Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
AU2003206690A1 (en) 2002-01-18 2003-07-30 Basf Aktiengesellschaft Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides
AU2003205656B2 (en) 2002-01-31 2007-09-06 Ciba Specialty Chemicals Holding Inc. Micropigment mixtures
ES2269978T3 (es) 2002-02-12 2007-04-01 Dsm Ip Assets B.V. Composiciones para filtros solares asi como dihidropiridinas y dihidropiranos.
WO2003068008A1 (en) 2002-02-14 2003-08-21 Dsm Ip Assets B.V. Water-dispersible coenzyme q10 dry powders
EP1340486A1 (de) 2002-03-01 2003-09-03 Cognis France S.A. Verwendung von Zuckerestern
AU2003217950A1 (en) 2002-03-05 2003-09-22 Cleveland State University Agglomerated particles for aerosol drug delivery
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
EP1482918A2 (de) 2002-03-09 2004-12-08 MSE Pharmazeutika GmbH Verwendung von ubichinonen zur beeinflussung der histaminwirkung zur behandlung von bronchitis, asthma und allergischen krankheiten
DE10254315A1 (de) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Emollients und kosmetische Zubereitungen
TW200304372A (en) 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
DE10212528A1 (de) 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Ölphasen für kosmetische Mittel
US7811594B2 (en) 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE10213957A1 (de) 2002-03-28 2003-10-09 Beiersdorf Ag Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
AU2003230750A1 (en) 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DE10217474A1 (de) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sonnenschutzemulsion mit Schaumspender
IL164795A0 (en) 2002-04-25 2005-12-18 Scripps Research Inst Treatment and prevention of pulmonary conditions
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
JP2005531570A (ja) 2002-05-23 2005-10-20 ユーエムディー， インコーポレイテッド 貫粘膜薬物送達及び凍結保護のための組成物及び方法
DE10223486A1 (de) 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
ES2269955T3 (es) 2002-06-03 2007-04-01 Ciba Specialty Chemicals Holding Inc. Formulaciones para proteccion de uv.
WO2003101402A2 (en) 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
DE10226018A1 (de) 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Zubereitungen mit konjugiertem Linolalkohol
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
WO2004003564A2 (de) 2002-06-26 2004-01-08 Europroteome Ag Tumormarker und ihre verwendung zur diagnose und therapie von tumorerkrankungen
WO2004010958A2 (en) 2002-07-31 2004-02-05 Shaklee Corporation A method for maximizing scalp health and inducing enhanced visual and tactile hair quality
US6953786B2 (en) 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
KR100484525B1 (ko) 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
US7241456B2 (en) 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
EP1421929A3 (de) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients und kosmetische Zubereitungen
DE10255195A1 (de) 2002-11-27 2004-06-09 Lipoid Gmbh Micellare wasserlösliche Konzentrate
DE10256881A1 (de) 2002-12-05 2004-06-24 Beiersdorf Ag Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
KR20050096936A (ko) 2003-01-15 2005-10-06 다우 글로벌 테크놀로지스 인크. 차가운 표면 위에서 동결시켜 수득한 약물 입자
DE602004028902D1 (de) 2003-01-20 2010-10-14 Basf Se Triazinderivate als uv-absorber
US20060140970A1 (en) 2003-01-23 2006-06-29 Adam Telerman Proteic binding partners of TCTP and methods of modulating tumor reversion or cell apoptosis
WO2004069216A1 (en) 2003-02-03 2004-08-19 Dsm Ip Assets B.V. Novel stabilized cinnamic ester sunscreen compositions
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (zh) * 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
BRPI0408994B1 (pt) 2003-03-24 2015-07-14 Ciba Sc Holding Ag Uso não terapêutico de derivados de triazina simétrica, sua preparação cosmética, bem como seu processo de preparação
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20110318405A1 (en) 2003-06-25 2011-12-29 Charles Erwin Chemical Combination and Method for Increasing Delivery of Coenzyme Q10
US20060035981A1 (en) 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
JP2007503418A (ja) 2003-08-27 2007-02-22 バイヤースドルフ・アクチエンゲゼルシヤフト 局所使用中に個別には感知不能になる外皮を有するカプセル
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
AU2004277951B2 (en) 2003-09-29 2010-11-11 Soft Gel Technologies, Inc. Solubilized CoQ-10
AU2004275451B2 (en) 2003-10-02 2010-11-25 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
DE10347218A1 (de) 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sonnenschutzmittel
DE10347940A1 (de) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Selbstemulgierende Zubereitungen
US20070243180A1 (en) 2003-10-31 2007-10-18 Hozumi Tanaka Composition Containing Reduced Coenzyme Q
US20070189994A1 (en) 2003-11-05 2007-08-16 Katja Berg Light protecting composition with reduced total amount of uv filter containing a polysiloxane-based uv filter
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
DE10354052A1 (de) 2003-11-17 2005-06-16 Beiersdorf Ag Kosmetikum mit empfindlichen Inhaltsstoffen
TW200524541A (en) 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
SI1718283T1 (sl) 2004-01-22 2013-06-28 University Of Miami Topične formulacije koencima Q10 in postopki uporabe
US20050226947A1 (en) 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
JP2007523156A (ja) 2004-02-19 2007-08-16 ケマファー インコーポレイティッド 皮膚状態の処置用の局所製剤
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
DE102004014615A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere
DE102004020627A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen
WO2005104213A2 (en) 2004-04-06 2005-11-03 Basf Aktiengesellschaft COSMETIC FORMULATIONS COMPRISING ZnO NANOPARTICLES
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
RU2375053C2 (ru) 2004-05-18 2009-12-10 Кемийски Инштитут Новая водорастворимая форма коэнзима q10 в форме комплекса включения с бета-циклодекстрином, способ ее получения и ее применение
WO2005112957A1 (en) 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
DE502005006284D1 (de) 2004-05-24 2009-01-29 Basf Se Keratin-bindende polypeptide
EP1768647B1 (en) 2004-06-17 2012-08-08 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent
ATE415976T1 (de) 2004-06-18 2008-12-15 Symrise Gmbh & Co Kg Brombeerextrakt
US20050288378A1 (en) 2004-06-21 2005-12-29 Xiaoqiang Yan Cancer chemotherapy
ES2380940T3 (es) 2004-06-28 2012-05-21 Dsm Ip Assets B.V. Composiciones cosméticas que contienen hidrolizados de proteína
AU2005262369B2 (en) 2004-07-01 2008-08-28 E-L Management Corp. Cosmetic compositions and methods containing a tanning agent and liposome-encapsulated ursolic acid
JP2006070016A (ja) 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CA2584138A1 (en) 2004-10-18 2006-04-27 Raphael C. Lee Methods and compositions for treatment of free radical injury
BRPI0517930A (pt) 2004-11-02 2008-10-21 Dsm Ip Assets Bv aditivo para preparações de protetor solar contra uv
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
EP1811977B1 (en) 2004-11-16 2018-01-10 Bioavailability, Inc. High concentration self-microemulsifying coenzyme q10 preparations for nutritional use
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
US20060154993A1 (en) 2004-12-17 2006-07-13 Littarru Gian P Method for treating and preventing male infertility
NO20045674D0 (no) 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20080207560A1 (en) 2005-01-07 2008-08-28 Ayako Harada Composition For External Use
CN102008729A (zh) 2005-01-07 2011-04-13 日本乐敦制药株式会社 外用组合物
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
DE102005007980A1 (de) 2005-02-22 2006-02-23 Clariant Gmbh Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse
WO2007040591A2 (en) 2005-03-01 2007-04-12 Jarrow Formulas, Inc. A ubiquinone composition and a container for its convenient transport and storage
EP1871389A2 (en) 2005-04-01 2008-01-02 Zymes, LLC Skin enrichment using coq10 as the delivery system
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
WO2006118988A2 (en) 2005-04-29 2006-11-09 University Of Tennessee Research Foundation Cellular biomarker antioxidant assay and uses thereof
US20060280691A1 (en) 2005-06-13 2006-12-14 University Of Alberta Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
ITPD20050224A1 (it) 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
EP1908459A4 (en) 2005-07-28 2010-07-14 Kaneka Corp COMPOSITION PREVENTING CANCER
US20070053985A1 (en) 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
US20070071779A1 (en) 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
US20070092469A1 (en) 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9265792B2 (en) 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
CA2631713A1 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
BRPI0619598A2 (pt) 2005-12-09 2011-10-11 Drugtech Corp composição de emulsão intravenosa de ácido graxo essencial e métodos de administração da mesma
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
CA2642096A1 (en) 2006-02-09 2008-02-28 Ocean Nutrition Canada Ltd. Coenzyme q10 production from marine bacteria
GB0603975D0 (en) 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
US8703195B2 (en) * 2006-03-10 2014-04-22 Biorem Ag Method for solubilising, dispersing and stabilising of substances, products manufactured according to the method as well as the use thereof
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
EP2005951A2 (en) 2006-03-29 2008-12-24 Kaneka Corporation Agent for improving nervous system cell functions
US7829080B2 (en) 2006-04-28 2010-11-09 Kaneka Corporation Stabilization method of reduced coenzyme Q10
EP2025662A4 (en) 2006-04-28 2011-07-27 Kaneka Corp PROCESS FOR PURIFYING REDUCED COENZYME Q10
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
MX352315B (es) 2006-05-02 2017-11-17 Univ Miami Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.
US20080020022A1 (en) 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US20080254017A1 (en) 2006-06-19 2008-10-16 Bodybio, Inc. Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
RU2315593C1 (ru) 2006-08-02 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Липосомальная композиция антиоксидантов для ингаляций при заболеваниях легких и верхних дыхательных путей
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP1897530A1 (en) 2006-09-08 2008-03-12 DSMIP Assets B.V. Skin care composition
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008058755A1 (en) 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
JPWO2008062559A1 (ja) 2006-11-22 2010-03-04 旭化成ファーマ株式会社 栄養補助食品、抗疲労作用剤又は持久力増強剤、機能性食品又は化粧料
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
US20080138326A1 (en) 2006-12-06 2008-06-12 Kaneka Corporation Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents
EP2111215A4 (en) 2007-01-18 2013-03-06 Mark A Pinsky MATERIALS AND METHOD FOR THE ADMINISTRATION OF ANTIOXIDANTS IN THE SKIN
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
KR100849537B1 (ko) * 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
CN101091890A (zh) 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
CA2700426C (en) 2007-09-25 2017-10-31 Galia Temtsin Krayz Compositions comprising lipophilic active compounds and method for their preparation
US8815567B2 (en) 2007-11-30 2014-08-26 E I Du Pont De Nemours And Company Coenzyme Q10 production in a recombinant oleaginous yeast
WO2009073843A1 (en) 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US8272253B2 (en) 2008-01-22 2012-09-25 Ct Associates, Inc. Particle concentration measurement technology
KR101003204B1 (ko) 2008-02-14 2010-12-21 메콕스큐어메드 주식회사 약물 전달용 고형 지질 나노입자, 그 제조방법, 및 그나노입자를 포함하는 주사제
US20100080785A1 (en) 2008-04-08 2010-04-01 Zymes, Llc Dried formulations
AU2009233785B2 (en) * 2008-04-11 2015-08-20 Berg Llc Methods and use of inducing apoptosis in cancer cells
WO2010008475A2 (en) 2008-06-23 2010-01-21 Virun, Inc. Compositions containing nono-polar compounds
US20100099775A1 (en) 2008-10-17 2010-04-22 Alpharx Inc. Method for ameliorating of post-anesthetic recovery
US20100129431A1 (en) 2008-11-24 2010-05-27 Alpharx Inc. Idebenone composition for the treatment of neurological disorders
US20100215725A1 (en) 2009-02-20 2010-08-26 Joseph Schwarz Pharmaceutical composition containing idebenone for the treatment of liver disorders
KR101066197B1 (ko) 2009-04-06 2011-09-20 한국생명공학연구원 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
KR20120060945A (ko) 2009-05-11 2012-06-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자, 다차원 세포내 분자 또는 환경적 영향인자를 사용한 대사적 장애의 치료 방법
US8408429B2 (en) * 2009-11-11 2013-04-02 The Clorox Company Bottle with integral dip tube
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
MY163995A (en) 2010-03-12 2017-11-15 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
US20120141446A1 (en) 2010-12-02 2012-06-07 Bhiku Patel Oral Nutritional Supplement Delivery System
TWI425914B (zh) 2011-03-21 2014-02-11 Food Industry Res & Dev Inst 含高濃度奈米／次微米疏水性機能化合物之水相分散液之製備方法
MY159478A (en) 2011-05-23 2017-01-13 Malaysian Palm Oil Board A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil
MX369543B (es) 2011-06-17 2019-11-12 Berg Llc Composiciones farmaceuticas inhalables.
CA2868326A1 (en) 2012-04-13 2013-10-17 Banner Pharmacaps, Inc. Soft elastic capsules containing tablets and liquid or semisolid fills and methods for their manufacture
WO2013175266A1 (en) 2012-05-21 2013-11-28 Chemi Nutra Inc. Method for increasing muscle mass and strength
WO2014138922A1 (en) 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
KR20150062802A (ko) 2013-11-29 2015-06-08 삼성전자주식회사 소수성 활성 성분을 포함하는 내부 리포좀을 포함하는 이중막 리포좀, 및 그의 용도
WO2015127537A1 (en) 2014-02-27 2015-09-03 B-Organic Films Corp. Bioactive agents included in functionalized starch having a single helix v-structure
CA2945323A1 (en) 2014-04-08 2015-10-15 University Of Massachusetts Food matrices and methods of making and using

Also Published As

Publication number Publication date
SG183508A1 (en) 2012-10-30
DK2544663T3 (en) 2018-04-16
IL221675B (en) 2018-06-28
CN102892412B (zh) 2015-09-30
CA2791693A1 (en) 2011-09-15
AU2020203490A1 (en) 2020-06-18
JP2013522233A (ja) 2013-06-13
AU2016200991B2 (en) 2017-12-21
BR112012022916A2 (pt) 2016-08-09
CL2012002507A1 (es) 2012-12-21
JP5968231B2 (ja) 2016-08-10
TW201141467A (en) 2011-12-01
EP3366280A1 (en) 2018-08-29
SG10201501872XA (en) 2015-05-28
AU2011224207A1 (en) 2012-09-13
TW201703761A (zh) 2017-02-01
CA3022054A1 (en) 2011-09-15
CO6620033A2 (es) 2013-02-15
MX2012010513A (es) 2013-01-18
NZ602057A (en) 2015-06-26
NZ701451A (en) 2016-09-30
CN102892412A (zh) 2013-01-23
KR20180112876A (ko) 2018-10-12
JP2021050221A (ja) 2021-04-01
TWI602562B (zh) 2017-10-21
JP6431003B2 (ja) 2018-11-28
US20110229554A1 (en) 2011-09-22
MY163995A (en) 2017-11-15
PE20130045A1 (es) 2013-01-28
TWI610671B (zh) 2018-01-11
AU2016200991A1 (en) 2016-03-24
EA032941B1 (ru) 2019-08-30
JP2016199573A (ja) 2016-12-01
AU2018202010B2 (en) 2020-02-27
PL2544663T3 (pl) 2018-09-28
JP6861682B2 (ja) 2021-04-21
CR20120507A (es) 2012-12-04
CN105168135A (zh) 2015-12-23
NZ720022A (en) 2018-07-27
MX344078B (es) 2016-12-05
WO2011112900A2 (en) 2011-09-15
KR20140021467A (ko) 2014-02-20
US20230165809A1 (en) 2023-06-01
CY1120290T1 (el) 2019-07-10
EP2544663B1 (en) 2018-01-03
KR101907411B1 (ko) 2018-10-12
HK1219055A1 (zh) 2017-03-24
ES2664793T3 (es) 2018-04-23
WO2011112900A3 (en) 2012-01-12
AU2011224207B2 (en) 2015-11-19
JP2019059734A (ja) 2019-04-18
EP2544663A2 (en) 2013-01-16
PT2544663T (pt) 2018-04-05
EP2544663A4 (en) 2013-10-30
KR102008658B1 (ko) 2019-08-08
EA201270735A1 (ru) 2013-02-28
CA2791693C (en) 2018-11-27
AU2018202010A1 (en) 2018-04-12
US11400058B2 (en) 2022-08-02
BR112012022916B1 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
HK1219055A1 (zh) 輔酶 的靜脈內製劑及其使用方法
HK1202244A1 (en) Prebiotic formulations and methods of use
ZA201300193B (en) Formulations of rifaximin and uses thereof
EP2654726A4 (en) SOLID DISPERSION FORMULATIONS AND METHODS OF USE
EP2563372A4 (en) PREBIOTIC FORMULATIONS AND METHODS OF USE
EP2536283B8 (en) Phenyl-heteroaryl derivatives and methods of use thereof
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
SI2603232T1 (sl) Stabilne formulacije linaklotida
EP2385944A4 (en) FLUORINATED COMPOUNDS AND METHODS OF USE
ZA201300930B (en) St-246 liquid formulations and methods
IL221043A0 (en) Modified release formulation and methods of use
EP2547340A4 (en) OPHTHALMIC FORMULATIONS OF CETIRICINE AND METHOD FOR THEIR USE
PL2525782T3 (pl) Preparaty nanonośników i sposoby ich wytwarzania
EP2385943A4 (en) FLUORINATED COMPOUNDS AND METHODS OF USE
EP2623593A4 (en) NOVEL AMINOTRANSFERASE AND ENCODING GENE, AND THE USE OF AMINOTRANSFERASE AND GENE
IL224192A (en) Compositions of Vitamin 14 – Epi Analogs d
EP2533762A4 (en) RETINOL FORMULATIONS AND METHOD FOR THEIR USE
EP2850044A4 (en) USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND IN MEDICAL IMAGING
GB2480998B (en) Expandable armrest of wheel chair
EP2525660A4 (en) FORMULATION WITH MODIFIED RELEASE AND USE METHOD
TWM385289U (en) Structure of chair footrest